THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act - Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling. Issues related to strengthening the resiliency of the U.S. medical supply chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY J CASEY | — |
Budget/Appropriations BUD
H.R. 5304, S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience. H.R. 4779 - National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY J CASEY | — |
Defense DEF
S. 2296 - National Defense Authorization Act for Fiscal Year 2026; H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027: Provisions related to supply chain resilience.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY J CASEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.